ArticleDermatology and therapy2026
Safety, Pharmacokinetics, and Efficacy of 1.5% Ruxolitinib Gel (HDM3010) in Adult Patients with Prurigo Nodularis: A Phase I/II, Randomized, Double-Blind, Vehicle-Controlled Multicenter Clinical Trial.
Chao Wu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.